Yesterday we took a look at three major pathways to insurance coverage of obesity-indicated GLP-1 drugs. We reviewed broad Medicare Part D coverage, a regulatory response and industry initiatives with some politics tossed in there to makes things slightly unpredictable.
Link to replay here.
Timestamps:
|
0:00 - 6:26 Introduction and three likely paths to reimbursement 6:27 - 8:08 Current law and Medicare Part D Coverage 8:08 - 11:00 Expanding Medicare Coverage; Treat and Reduce Obesity Act of 2023 11:00 - 13:10 The Congressional Budget Office's issues 13:10 - 20:24 Redefining Obesity; possible demos and interagency squabbles between the FDA and CMS; significant tradeoffs with price 20:24 - 24:45 A voluntary private sector demo? Not likely but not impossible 24:45 - 32:26 What to watch |
Let me know if you have any questions or would like to discuss.
Emily Evans
Managing Director – Health Policy
X
LinkedIn
Calendly Meeting Set-up
